Beyond Discovery. Toward Impact.
Science only matters when it reaches those who need it.
That is the standard we hold ourselves to.
Akrocell Biosciences did not begin in veterinary medicine.
The company was founded in April 2021 on a proprietary platform for constructing macro-scale organoids
for advanced tissue-engineering therapeutics in human medicine.
Building organoids at scale demanded one thing above all:
the ability to expand stem cells reliably, consistently, and in large quantity
— and that became the defining technical focus of our team.
In 4Q 2024, we made a deliberate pivot.
Not away from that science — but toward the market where it could move fastest.
Companion animal medicine presented something rare:
a field with profound unmet need, a regulatory pathway that rewards innovation,
and a set of biological problems that our platform was uniquely positioned to solve.
The same technical barriers that had limited the entire industry
— the inability to culture companion animal stem cells beyond early passages
without losing consistency or biological integrity
— were precisely the kind of problems our team had spent years learning to solve in human therapeutics.
HYCC™ (High Yield Combinatorial Culture) is the result.
A platform built on human stem cell R&D expertise, applied to solve a problem
that veterinary medicine could not crack on its own.
We are not a research group looking for applications.
We are a platform company moving toward the market
— with the science to back it, and the business experience to close it.
History
April 2021 Founded in Seoul, Korea
December 2021 Head office established at Seoul BioHub
February 2022 Research lab established
August 2022 Seed funding secured (approx. US$700K)
January 2023 Research lab relocated to Bio Core Facility, Seoul St. Mary's Hospital, Catholic University of Korea
November 2024 Strategic pivot initiated — companion animal stem cell-derived exosome therapeutics
April 2025 Strategic MOU signed with Jeonnam Bio Foundation
August 2025 Research collaboration MOU signed with Jeonnam National University Veterinary Teaching Hospital
October 2025 Head office relocated to Biopharma HQ, Jeonnam Bio Foundation (Hwasun, Jeonnam)
November 2025 Research lab relocated (Anyang, Gyeonggi)
